Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 16, 2017. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not contain company-wide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on specific share transactions.
| Transaction Date | Instrument | Price | Volume |
|---|---|---|---|
| October 12, 2017 | Ordinary Shares (GBP) | £15.2425 | Various (105.097 to 262.743 shares) |
| October 12, 2017 | American Depositary Shares (USD) | $40.9497 | 330.748 ADSs |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details routine increases in notional interest in shares resulting from dividend reinvestment.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions described are automatic reinvestments of dividends paid on October 12, 2017, under the Company's Deferred Investment Award Programme.
Investor Verification Checklist
- Verify the dividend payment date of October 12, 2017, to confirm the timing of the reinvestment.
- Confirm the share price of £15.2425 and $40.9497 against market data for October 12, 2017.
- Note that these transactions represent notional interest increases, not open-market purchases by executives.
- Identify the specific executives involved: Ms E Walmsley (CEO), Mr R G Connor (President, Global Manufacturing & Supply), Mr B McNamara (CEO, GSK Consumer Healthcare), Mr D S Redfern (Chief Strategy Officer), Ms C Thomas (SVP, HR), and Dr P J T Vallance (President, R&D).